ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

Two university spin-offs emerge

by Michael McCoy
July 4, 2016 | APPEARED IN VOLUME 94, ISSUE 27

Morphic Therapeutic has raised $51.5 million in a first round of venture capital funding from investors including Pfizer and AbbVie. Founded to translate advances from the lab of Harvard Medical School professor Timothy A. Springer, Morphic is developing small molecules that treat disease by targeting cell membrane proteins called integrins. Meanwhile, Storm Therapeutics has raised about $16 million in a first round of funding from investors including Pfizer and Merck & Co. A spin-off from the University of Cambridge’s Gurdon Institute, Storm seeks to develop small-molecule drugs that target RNA-modifying enzymes involved in cancer.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment